NEW YORK (AP) – AstraZeneca PLC and Abbott Laboratories said they are ending a partnership on a cholesterol drug that was rejected by the Food and Drug Administration earlier this year.
AstraZeneca is discontinuing development of Certriad, a drug that combined Abbott’s drug TriLipix with AstraZeneca’s Crestor, because “the development of Certriad is no longer commercially attractive.” The partnership between the companies will end Jan. 22. The companies filed for approval of Certriad in June 2009, but the FDA asked the companies for more data on March 30.
Date: December 22, 2010
Source: Associated Press
Filed Under: Drug Discovery